Sacran polysaccharide improves atopic dermatitis through inhibiting Th2 type immune response.
Life Sci
; 288: 120205, 2022 Jan 01.
Article
em En
| MEDLINE
| ID: mdl-34871665
ABSTRACT
AIMS:
This study was aimed to explore whether sacran polysaccharide has a therapeutic effect on atopic dermatitis (AD) and its possible mechanisms. MATERIALS ANDMETHODS:
2, 4-dinitrochlorobenzene (DNCB)-induced AD mice were treated with 0.2% Sacran, 0.5% Sacran and 0.1% tacrolimus. Through scoring dermatitis severity, measuring ear thickness, cracking behavior, open field test, we evaluated the therapeutic effect of Sacran on DNCB-induced AD mice. CD4+ T cells and CD8+ T cells were evaluated by flow cytometry. The relative expression of Ifng and Il4 were measured by real-time quantitative PCR. KEYFINDINGS:
Sacran could relieved the symptoms of DNCB-induced AD mice, such as AD score, ear thickness, and IgE release. Sacran may alleviate dermatitis by inhibiting Th2 activation and reducing IgE release.SIGNIFICANCE:
Our research further proved that polysaccharide Sacran has anti-dermatitis effects, and also clarified its mechanism of alleviating dermatitis by inhibiting the activation of Th2 cells and reducing the release of IgE, which provides a theoretical basis for the future clinical transformation of polysaccharide Sacran.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Polissacarídeos
/
Imunoglobulina E
/
Células Th2
/
Dermatite Atópica
/
Dinitroclorobenzeno
/
Inflamação
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article